Article
Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Cancer research - 15 Jan 2001
Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y
Abstract excerpt
NB-506 is a topoisomerase I (top1) inhibitor in clinical trials. In this study, we used a series of camptothecin (CPT)-resistant cell lines with known top1 alterations. We show that three mutations in different domains of the top1 enzyme that confer CPT resistance also confer cross-resistance to NB-506. The CPT-resistant cell lines and corresponding mutations were: human prostate carcinoma cells DU-145/RC1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.